Amgen's (AMGN) Market Perform Rating Reiterated at Leerink Swann


's stock had its "market perform" rating restated by equities research analysts at Leerink Swann in a research report issued to clients and investors on Friday. They presently have a $201.00 target price on the medical research company's stock.



from Biotech News